




RealRate

MEDICINAL PRODUCTS 2020

Intellia Therapeutics Inc.
Rank 15 of 52





RealRate

MEDICINAL PRODUCTS 2020

Intellia Therapeutics Inc.
Rank 15 of 52



The relative strengths and weaknesses of Intellia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intellia Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Intellia Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 84%, being 88% points above the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	289,481
Assets, Non-Current	26,803
General and Administrative Expense	41,058
Goodwill	0
Liabilities, Current	35,633
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	289
Other Expenses	0
Other Liabilities	0
Other Net Income	6,835
Other Revenues	43,103
Property, Plant and Equipment, Net	17,996
Research and Development	108,413

Output Variable	Value in 1000 USD
Liabilities	35,633
Assets	334,280
Expenses	149,471
Revenues	43,103
Stockholders Equity	298,647
Net Income	-99,533
Comprehensive Net Income	-99,388
Economic Capital Ratio	84%